NCT00793091
Unknown
Phase 2
A Phase 2, Randomized, Placebo-Controlled, Double-Masked, Multicenter Safety and Efficacy Study of C-KAD Ophthalmic Solution in Patients With Loss of Visual Acuity Due to Age-Related Cataract
ConditionsCataract
Overview
- Phase
- Phase 2
- Intervention
- C-KAD Ophthalmic Solution
- Conditions
- Cataract
- Sponsor
- Chakshu Research, Inc.
- Enrollment
- 80
- Locations
- 4
- Primary Endpoint
- Best-corrected visual acuity by ETDRS
- Last Updated
- 17 years ago
Overview
Brief Summary
The purpose of this study is to determine the safety and efficacy of C-KAD Ophthalmic Solution in improving visual acuity relative to placebo in patients with age-related cataract
Investigators
Eligibility Criteria
Inclusion Criteria
- •Presence of age-related cataract in the study eye
- •Best-corrected visual acuity of 20/25 to 20/50 in the study eye
Exclusion Criteria
- •Any other clinical condition in the eye that may compromise vision
- •Presence or History of Glaucoma
- •Presence or history of diabetes
- •Use of eyedrops
- •Use of steroids
Arms & Interventions
1
Intervention: C-KAD Ophthalmic Solution
2
Intervention: Placebo
Outcomes
Primary Outcomes
Best-corrected visual acuity by ETDRS
Time Frame: 120 Days
Study Sites (4)
Loading locations...
Similar Trials
Unknown
Phase 2
Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear CataractNuclear CataractNCT00825721Chakshu Research, Inc.81
Completed
Not Applicable
An Open-Label Study of an Ophthalmic Solution to Reduce Intraocular Pressure in Patients With Ocular HypertensionOcular HypertensionNCT00825396Chakshu Research, Inc.12
Completed
Phase 2
Safety and Efficacy of KPI-121 in Subjects With Dry Eye DiseaseDry Eye SyndromesKeratoconjunctivitis SiccaNCT02188160Kala Pharmaceuticals, Inc.150
Unknown
Phase 2
An Open-Label Study of the Effect of an Ophthalmic Solution on Asteroid HyalosisAsteroid HyalosisNCT00825942Chakshu Research, Inc.20
Completed
Phase 3
Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy VolunteersAllergic ConjunctivitisNCT01159015Bausch & Lomb Incorporated534